Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from 60 Degrees Pharmaceuticals, Inc. ( (SXTP) ).
On September 3, 2025, 60 Degrees Pharmaceuticals, Inc. entered into an At-The-Market Sales Agreement with H.C. Wainwright & Co., LLC to offer and sell shares of its common stock, potentially raising up to $1,397,533. The agreement allows the company flexibility in selling shares while Wainwright acts as the sales agent, earning a 3% commission on sales. Additionally, on the same date, the company terminated a previous sales agreement with Wallachbeth Capital LLC, effective immediately, releasing both parties from any obligations.
The most recent analyst rating on (SXTP) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on 60 Degrees Pharmaceuticals, Inc. stock, see the SXTP Stock Forecast page.
Spark’s Take on SXTP Stock
According to Spark, TipRanks’ AI Analyst, SXTP is a Underperform.
SXTP’s overall stock score is weighed down by poor financial performance and weak technical indicators. While the recent capital injection is a positive development, significant challenges in profitability and valuation remain.
To see Spark’s full report on SXTP stock, click here.
More about 60 Degrees Pharmaceuticals, Inc.
Average Trading Volume: 574,120
Technical Sentiment Signal: Sell
Current Market Cap: $6.07M
See more insights into SXTP stock on TipRanks’ Stock Analysis page.